QS21
Phase 1Biologic
QS21 is one of 38 biologic programs targeting Breast Cancer. It is currently in Phase 1.
2
Indications
15
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
702 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Adenocard
AstellasPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Duragesic
CCephalon
Preclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
QS21
MMemorial Sloan Kettering Cancer Center
Phase 1
Bisphosphonate
AmgenPreclinical
4SCAR T Cells
SShenzhen Geno-Immune Medical Institute
Preclinical
Metfomin
UUniversity of Texas Southwestern Medical Center
Preclinical
Perflutren Lipid Microsphere
IImaRx Therapeutics
Preclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer4 trials
Breast Cancer3 trials
Melanoma2 trials
Peritoneal Cancer1 trial
4 more indications
Chronic Myelogenous Leukemia1 trial
Colorectal Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for QS21. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details